Skip to main content
Top
Published in: Endocrine 2/2017

01-05-2017 | Review

Insights into the relationships between diabetes, prediabetes, and cancer

Authors: Lorenzo Scappaticcio, Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Diabetes mellitus and cancer are two growing health problems. They have in common many modifiable risk factors including sex, age, obesity, physical activity, diet, alcohol, and smoking, and have a long latency before overtly manifesting. Patients with diabetes experience a roughly 20–25% higher cancer incidence compared to individuals without diabetes, and it depends on cancer site. Moreover, patients with diabetes who further develop cancer have increased early and late mortality in comparison with cancer patients without diabetes. Prediabetes and metabolic syndrome are also related to an increased risk of developing and die from cancer. Possible mechanisms linking diabetes and prediabetes with cancer include hyperglycemia (endogenous or exogenous), hyperinsulinemia, and alterations of insulin-like growth factor system, chronic subclinical inflammation, abnormalities in sex hormone metabolism, and adipokines. It becomes crucial to define the right orientation of the associations between diabetes and cancer in order to identify the modifiable pathogenic mechanisms. The common soil hypothesis claims that prediabetes and diabetes, as well as metabolic syndrome, may be considered a surrogate sign for dietary risk factors of cancer. The clepsydra of foods may help choose foods associated with healthy benefit while avoiding foods associated with harm, including cancer.
Literature
2.
go back to reference World Health Organization (WHO), International Agency for Research on Cancer (IARC)—GLOBOCAN 2012 and Cancer fact sheets World Health Organization (WHO), International Agency for Research on Cancer (IARC)—GLOBOCAN 2012 and Cancer fact sheets
3.
go back to reference World Health Organization (WHO), Cancer fact sheet N° 97 Updated February 2015 World Health Organization (WHO), Cancer fact sheet N° 97 Updated February 2015
4.
go back to reference E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. Albright, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modeling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. Albright, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modeling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed
5.
6.
go back to reference M. Arnold, N. Pandeya, G. Byrnes et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed M. Arnold, N. Pandeya, G. Byrnes et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed
7.
go back to reference S.A. Tanumihardjo, C. Anderson, M. Kaufer-Horwitz et al. Poverty, obesity, and malnutrition: an international perspective recognizing the paradox. J. Am. Diet. Assoc. 107, 1966–1972 (2007)CrossRefPubMed S.A. Tanumihardjo, C. Anderson, M. Kaufer-Horwitz et al. Poverty, obesity, and malnutrition: an international perspective recognizing the paradox. J. Am. Diet. Assoc. 107, 1966–1972 (2007)CrossRefPubMed
10.
go back to reference K. Esposito, F. Ciardiello, D. Giugliano, Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46, 39–42 (2014)CrossRefPubMed K. Esposito, F. Ciardiello, D. Giugliano, Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46, 39–42 (2014)CrossRefPubMed
11.
go back to reference K. Ranc, M.E. Jørgensen, S. Friis, B. Carstensen, Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57(5), 927–934 (2014)CrossRefPubMed K. Ranc, M.E. Jørgensen, S. Friis, B. Carstensen, Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57(5), 927–934 (2014)CrossRefPubMed
12.
go back to reference A. Renehan, U. Smith, M.S. Kirkman, Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733), 2201–2 (2010). CrossRefPubMed A. Renehan, U. Smith, M.S. Kirkman, Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733), 2201–2 (2010). CrossRefPubMed
13.
go back to reference S.M. Bluethmann, A.B. Mariotto, J.H. Rowland, Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol. Biomarkers Prev. 25(7), 1029–1036 (2016)CrossRefPubMedPubMedCentral S.M. Bluethmann, A.B. Mariotto, J.H. Rowland, Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol. Biomarkers Prev. 25(7), 1029–1036 (2016)CrossRefPubMedPubMedCentral
14.
go back to reference E.C. de Haas, S.F. Oosting, J.D. Lefrandt et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 11, 193–203 (2010)CrossRefPubMed E.C. de Haas, S.F. Oosting, J.D. Lefrandt et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 11, 193–203 (2010)CrossRefPubMed
15.
16.
go back to reference S.C. Darby, M. Ewertz, P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013)CrossRefPubMed S.C. Darby, M. Ewertz, P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013)CrossRefPubMed
17.
go back to reference T. Tuffier, Diabete et neoplasmes. Arch. Gen. de Med. 7, 129–140 (1988) T. Tuffier, Diabete et neoplasmes. Arch. Gen. de Med. 7, 129–140 (1988)
18.
go back to reference Y. Shi, F.B. Hu, The global implications of diabetes and cancer. Lancet 383(9933), 1947–1948 (2014). 7CrossRefPubMed Y. Shi, F.B. Hu, The global implications of diabetes and cancer. Lancet 383(9933), 1947–1948 (2014). 7CrossRefPubMed
19.
go back to reference I.C. Lega, A.S. Wilton, P.C. Austin et al. The temporal relationship between diabetes and cancer. Cancer. 17, 2731–2738 (2016) I.C. Lega, A.S. Wilton, P.C. Austin et al. The temporal relationship between diabetes and cancer. Cancer. 17, 2731–2738 (2016)
20.
go back to reference Y. Handelsman, D. Leroith, Z.T. Bloomgarden et al. Diabetes and cancer—an AACE/ACE consensus statement. Endocr. Pract. 19(4), 675–693 (2013)CrossRefPubMed Y. Handelsman, D. Leroith, Z.T. Bloomgarden et al. Diabetes and cancer—an AACE/ACE consensus statement. Endocr. Pract. 19(4), 675–693 (2013)CrossRefPubMed
21.
go back to reference A. Satija, D. Spiegelman, E. Giovannucci, F.B. Hu, Type 2 diabetes and risk of cancer. BMJ 2, 350 (2015). g7707 A. Satija, D. Spiegelman, E. Giovannucci, F.B. Hu, Type 2 diabetes and risk of cancer. BMJ 2, 350 (2015). g7707
22.
go back to reference C. De Nunzio, A. Tubaro, Prostate cancer: diabetes and prostate cancer - an open debate. Nat. Rev. Urol. 10, 12–14 (2013)CrossRefPubMed C. De Nunzio, A. Tubaro, Prostate cancer: diabetes and prostate cancer - an open debate. Nat. Rev. Urol. 10, 12–14 (2013)CrossRefPubMed
23.
go back to reference D. Bansal, A. Bhansali, G. Kapil, K. Undela, P. Tiwari, Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 16, 151–158 (2013). S1CrossRefPubMed D. Bansal, A. Bhansali, G. Kapil, K. Undela, P. Tiwari, Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 16, 151–158 (2013). S1CrossRefPubMed
24.
go back to reference K.K. Tsilidis, N.E. Allen, P.N. Appleby et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int. J. Cancer 136, 372–381 (2015)CrossRefPubMed K.K. Tsilidis, N.E. Allen, P.N. Appleby et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int. J. Cancer 136, 372–381 (2015)CrossRefPubMed
26.
go back to reference Q. Li, S. Kuriyama, M. Kakizaki et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki cohort study. Cancer Causes Control 21, 1025–1032 (2010)CrossRefPubMed Q. Li, S. Kuriyama, M. Kakizaki et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki cohort study. Cancer Causes Control 21, 1025–1032 (2010)CrossRefPubMed
27.
go back to reference L. Bensimon, H. Yin, S. Suissa, M.N. Pollak, L. Azoulay, Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329–338 (2014)CrossRefPubMed L. Bensimon, H. Yin, S. Suissa, M.N. Pollak, L. Azoulay, Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329–338 (2014)CrossRefPubMed
28.
go back to reference S.R. Seshasai, S. Kaptoge, A. Thompson et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829–841 (2011)CrossRef S.R. Seshasai, S. Kaptoge, A. Thompson et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829–841 (2011)CrossRef
29.
go back to reference R. Dankner, P. Boffetta, R.D. Balicer et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183(12), 1098–1106 (2016). 15CrossRefPubMed R. Dankner, P. Boffetta, R.D. Balicer et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183(12), 1098–1106 (2016). 15CrossRefPubMed
30.
go back to reference K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2, 350 (2015). g7607 K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2, 350 (2015). g7607
31.
go back to reference A.G. Tabak, M. Jokela, T.N. Akbaraly et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009)CrossRefPubMedPubMedCentral A.G. Tabak, M. Jokela, T.N. Akbaraly et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009)CrossRefPubMedPubMedCentral
32.
go back to reference E. Giovannucci, D. Michaud, The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132, 2208–2225 (2007)CrossRefPubMed E. Giovannucci, D. Michaud, The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132, 2208–2225 (2007)CrossRefPubMed
33.
go back to reference J.A. Johnson, S.L. Bowker, Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25–31 (2011)CrossRefPubMed J.A. Johnson, S.L. Bowker, Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25–31 (2011)CrossRefPubMed
34.
go back to reference B.B. Barone, H.C. Yeh, C.F. Snyder et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33, 931–939 (2010)CrossRefPubMedPubMedCentral B.B. Barone, H.C. Yeh, C.F. Snyder et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33, 931–939 (2010)CrossRefPubMedPubMedCentral
35.
go back to reference B.B. Barone, H.C. Yeh, C.F. Snyder et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008)CrossRefPubMedPubMedCentral B.B. Barone, H.C. Yeh, C.F. Snyder et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008)CrossRefPubMedPubMedCentral
36.
go back to reference A.G. Renehan, H.C. Yeh, J.A. Johnson et al. Diabetes and cancer evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55, 1619–1632 (2012)CrossRefPubMed A.G. Renehan, H.C. Yeh, J.A. Johnson et al. Diabetes and cancer evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55, 1619–1632 (2012)CrossRefPubMed
37.
go back to reference J.M. Baena-Díez, J. Peñafiel, I. Subirana et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 11, 1987–1995 (2016) J.M. Baena-Díez, J. Peñafiel, I. Subirana et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 11, 1987–1995 (2016)
38.
go back to reference M. Tancredi, A. Rosengren, A.M. Svensson et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015)CrossRefPubMed M. Tancredi, A. Rosengren, A.M. Svensson et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015)CrossRefPubMed
39.
go back to reference A. Rawshani, A.M. Svensson, B. Zethelius et al. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern. Med. 176(8), 1146–1154 (2016). 1CrossRefPubMed A. Rawshani, A.M. Svensson, B. Zethelius et al. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern. Med. 176(8), 1146–1154 (2016). 1CrossRefPubMed
40.
go back to reference B. Carstensen, S.H. Read, S. Friis et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5), 980–988 (2016)CrossRefPubMedPubMedCentral B. Carstensen, S.H. Read, S. Friis et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5), 980–988 (2016)CrossRefPubMedPubMedCentral
41.
go back to reference A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367–377 (2008)CrossRefPubMedPubMedCentral A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367–377 (2008)CrossRefPubMedPubMedCentral
42.
go back to reference I.J. Neeland, A.T. Turer, C.L. Ayers et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308, 1150–1159 (2012)CrossRefPubMedPubMedCentral I.J. Neeland, A.T. Turer, C.L. Ayers et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308, 1150–1159 (2012)CrossRefPubMedPubMedCentral
43.
go back to reference K. Bhaskaran, I. Douglas, H. Forbes et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384(9945), 755–765 (2014). 30CrossRefPubMedPubMedCentral K. Bhaskaran, I. Douglas, H. Forbes et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384(9945), 755–765 (2014). 30CrossRefPubMedPubMedCentral
44.
go back to reference K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed
45.
go back to reference X. Yang, G.T.C. Ko, W.Y. So et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59, 1254–1260 (2010)CrossRefPubMedPubMedCentral X. Yang, G.T.C. Ko, W.Y. So et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59, 1254–1260 (2010)CrossRefPubMedPubMedCentral
47.
go back to reference C. Hope, A. Robertshaw, K.L. Cheung et al. Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet. Med. 8, 1013–1025 (2016) C. Hope, A. Robertshaw, K.L. Cheung et al. Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet. Med. 8, 1013–1025 (2016)
48.
go back to reference R. Vigneri, I.D. Goldfine, L. Frittitta, Insulin, insulin receptors, and cancer. J. Endocrinol. Invest. 12, 1365–1376 (2016) R. Vigneri, I.D. Goldfine, L. Frittitta, Insulin, insulin receptors, and cancer. J. Endocrinol. Invest. 12, 1365–1376 (2016)
49.
go back to reference NCD Risk Factor Collaboration (NCD-RisC), Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387, 1377–1396 (2016)CrossRef NCD Risk Factor Collaboration (NCD-RisC), Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387, 1377–1396 (2016)CrossRef
50.
go back to reference B. Lauby-Secretan, C. Scoccianti, D. Loomis et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 375(8), 794–798 (2016). 25CrossRefPubMedPubMedCentral B. Lauby-Secretan, C. Scoccianti, D. Loomis et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 375(8), 794–798 (2016). 25CrossRefPubMedPubMedCentral
51.
go back to reference P.T. Campbell, Obesity: a certain and avoidable cause of cancer. Lancet 384(9945), 727–8 (2014). 30CrossRefPubMed P.T. Campbell, Obesity: a certain and avoidable cause of cancer. Lancet 384(9945), 727–8 (2014). 30CrossRefPubMed
52.
go back to reference M. Arnold, M. Leitzmann, H. Freisling et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 41, 8–15 (2016)CrossRefPubMed M. Arnold, M. Leitzmann, H. Freisling et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 41, 8–15 (2016)CrossRefPubMed
53.
go back to reference International Agency for Research on Cancer. IARC handbooks of cancer prevention: weight control and physical activity. (IARC Press, Lyon), (2002). Vol. 6 International Agency for Research on Cancer. IARC handbooks of cancer prevention: weight control and physical activity. (IARC Press, Lyon), (2002). Vol. 6
54.
go back to reference A.G. Renehan, M. Tyson, M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–78 (2008)CrossRefPubMed A.G. Renehan, M. Tyson, M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–78 (2008)CrossRefPubMed
55.
go back to reference N.M. Iyengar, C.A. Hudis, A.J. Dannenberg, Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297–309 (2015)CrossRefPubMed N.M. Iyengar, C.A. Hudis, A.J. Dannenberg, Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297–309 (2015)CrossRefPubMed
56.
go back to reference S.D. Hursting, J. Digiovanni, A.J. Dannenberg et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5, 1260–1272 (2012)CrossRef S.D. Hursting, J. Digiovanni, A.J. Dannenberg et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5, 1260–1272 (2012)CrossRef
57.
go back to reference N. Parekh, Y. Lin, R.B. Hayes et al. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4), 631–642 (2010)CrossRefPubMed N. Parekh, Y. Lin, R.B. Hayes et al. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4), 631–642 (2010)CrossRefPubMed
58.
go back to reference M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004)CrossRefPubMed M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004)CrossRefPubMed
59.
go back to reference K.K. Wong, J.A. Engelman, L.C. Cantley, Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87–90 (2010)CrossRefPubMed K.K. Wong, J.A. Engelman, L.C. Cantley, Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87–90 (2010)CrossRefPubMed
60.
go back to reference R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011)CrossRefPubMed R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011)CrossRefPubMed
61.
go back to reference E. Barrett-Connor, K.T. Khaw, S.S. Yen, Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 132, 895–901 (1990)CrossRefPubMed E. Barrett-Connor, K.T. Khaw, S.S. Yen, Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 132, 895–901 (1990)CrossRefPubMed
62.
go back to reference D. Housa, J. Housova, Z. Vernerova, M. Haluzik, Adipocytokines and cancer. Physiol. Res. 55, 233–244 (2006)PubMed D. Housa, J. Housova, Z. Vernerova, M. Haluzik, Adipocytokines and cancer. Physiol. Res. 55, 233–244 (2006)PubMed
63.
go back to reference A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed
64.
go back to reference Y. Huang, X. Cai, M. Qiu et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57, 2261–2269 (2014)CrossRefPubMed Y. Huang, X. Cai, M. Qiu et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57, 2261–2269 (2014)CrossRefPubMed
65.
go back to reference R.A. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108, 3B–24B (2011)CrossRefPubMed R.A. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108, 3B–24B (2011)CrossRefPubMed
66.
go back to reference M. Buysschaert, J.L. Medina, M. Bergman, A. Shah, J. Lonier, Prediabetes and associated disorders. Endocrine 48(2), 371–393 (2015)CrossRefPubMed M. Buysschaert, J.L. Medina, M. Bergman, A. Shah, J. Lonier, Prediabetes and associated disorders. Endocrine 48(2), 371–393 (2015)CrossRefPubMed
67.
go back to reference O. Tabak, R. Gelisgen, H. Erman et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin. Invest. Med. 34, E163–E171 (2011)CrossRefPubMed O. Tabak, R. Gelisgen, H. Erman et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin. Invest. Med. 34, E163–E171 (2011)CrossRefPubMed
68.
go back to reference C.S. Pereira, P. Molz, R.P. Palazzo et al. DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat. Res. 753, 76–81 (2013)CrossRefPubMed C.S. Pereira, P. Molz, R.P. Palazzo et al. DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat. Res. 753, 76–81 (2013)CrossRefPubMed
69.
go back to reference M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)CrossRef M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)CrossRef
70.
go back to reference P. Stattin, O. Björ, P. Ferrari et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561–567 (2007)CrossRefPubMed P. Stattin, O. Björ, P. Ferrari et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561–567 (2007)CrossRefPubMed
71.
go back to reference M. Iwatsuki, K. Mimori, T. Yokobori et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101, 293–299 (2010)CrossRefPubMed M. Iwatsuki, K. Mimori, T. Yokobori et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101, 293–299 (2010)CrossRefPubMed
72.
go back to reference X.H. Zhou, Q. Qiao, B. Zethelius et al. Diabetes, prediabetes and cancer mortality. Diabetologia 53, 1867–1876 (2010)CrossRefPubMed X.H. Zhou, Q. Qiao, B. Zethelius et al. Diabetes, prediabetes and cancer mortality. Diabetologia 53, 1867–1876 (2010)CrossRefPubMed
73.
go back to reference S. Gao, A. Li, F. Liu et al. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24, 725–737 (2013)CrossRefPubMedPubMedCentral S. Gao, A. Li, F. Liu et al. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24, 725–737 (2013)CrossRefPubMedPubMedCentral
74.
go back to reference D. Giugliano, M.I. Maiorino, K. Esposito, Linking prediabetes and cancer: a complex issue. Diabetologia 58(1), 201–202 (2015)CrossRefPubMed D. Giugliano, M.I. Maiorino, K. Esposito, Linking prediabetes and cancer: a complex issue. Diabetologia 58(1), 201–202 (2015)CrossRefPubMed
75.
go back to reference K.-H. Wagner, H. Brath, A global view on the development of non communicable diseases. Prev. Med. 54(suppl), S38–S41 (2012)CrossRefPubMed K.-H. Wagner, H. Brath, A global view on the development of non communicable diseases. Prev. Med. 54(suppl), S38–S41 (2012)CrossRefPubMed
76.
go back to reference M. Aguilar, T. Bhuket, S. Torres et al. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313(19), 1973–1974 (2015). 19CrossRefPubMed M. Aguilar, T. Bhuket, S. Torres et al. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313(19), 1973–1974 (2015). 19CrossRefPubMed
77.
go back to reference K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45(3), 362–364 (2014)CrossRefPubMed K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45(3), 362–364 (2014)CrossRefPubMed
78.
go back to reference K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12), 1301–1309 (2013)CrossRefPubMed K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12), 1301–1309 (2013)CrossRefPubMed
79.
go back to reference K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45(1), 28–36 (2014)CrossRefPubMed K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45(1), 28–36 (2014)CrossRefPubMed
80.
81.
go back to reference J.R. Zhou, G.L. Blackburn, W.A. Walker, Symposium introduction: metabolic syndrome and the onset of cancer. Am. J. Clin. Nutr. 86, s817–s819 (2007)CrossRefPubMed J.R. Zhou, G.L. Blackburn, W.A. Walker, Symposium introduction: metabolic syndrome and the onset of cancer. Am. J. Clin. Nutr. 86, s817–s819 (2007)CrossRefPubMed
82.
go back to reference K. Esposito, P. Chiodini, A. Colao et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012)CrossRefPubMedPubMedCentral K. Esposito, P. Chiodini, A. Colao et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012)CrossRefPubMedPubMedCentral
83.
go back to reference J.L. Harding, M. Sooriyakumaran, K.J. Anstey et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J. Hypertens. 34(1), 149–155 (2016)CrossRefPubMed J.L. Harding, M. Sooriyakumaran, K.J. Anstey et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J. Hypertens. 34(1), 149–155 (2016)CrossRefPubMed
84.
go back to reference W.H. Chow, G. Gridley, J.F. Fraumani Jr, B. Jarvholm, Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000)CrossRefPubMed W.H. Chow, G. Gridley, J.F. Fraumani Jr, B. Jarvholm, Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000)CrossRefPubMed
85.
go back to reference N.J. Kocher, C. Rjepaj, H. Robyak et al. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. (2016). doi:10.1007/s00345-016-1850-2 N.J. Kocher, C. Rjepaj, H. Robyak et al. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. (2016). doi:10.​1007/​s00345-016-1850-2
86.
go back to reference N. Hayashi, M. Matsushima, T. Yamamoto et al. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 109(4), 515–519 (2012)CrossRefPubMed N. Hayashi, M. Matsushima, T. Yamamoto et al. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 109(4), 515–519 (2012)CrossRefPubMed
87.
go back to reference H. Jafri, A.A. Alsheikh-Ali, R.H. Karas, Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipidaltering therapy. J. Am. Coll. Cardiol. 55, 2846–2854 (2010)CrossRefPubMed H. Jafri, A.A. Alsheikh-Ali, R.H. Karas, Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipidaltering therapy. J. Am. Coll. Cardiol. 55, 2846–2854 (2010)CrossRefPubMed
88.
go back to reference M. Ezzati, E. Riboli, Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369, 954–964 (2013)CrossRefPubMed M. Ezzati, E. Riboli, Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369, 954–964 (2013)CrossRefPubMed
90.
go back to reference C. Micucci, D. Valli, G. Matacchione, A. Catalano, Current perspectives between metabolic syndrome and cancer. Oncotarget. 25, 38959–38972 (2016) C. Micucci, D. Valli, G. Matacchione, A. Catalano, Current perspectives between metabolic syndrome and cancer. Oncotarget. 25, 38959–38972 (2016)
91.
go back to reference P.C. Calder, N. Ahluwalia, F. Brouns et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 106(Suppl 3), S5–78 (2011)CrossRefPubMed P.C. Calder, N. Ahluwalia, F. Brouns et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 106(Suppl 3), S5–78 (2011)CrossRefPubMed
93.
go back to reference F.E. Deng, N. Shivappa, Y. Tang et al. Association between diet-related inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on prediabetics: findings from NHANES III. Eur. J. Nutr. (2016). doi:10.1007/s00394-016-1158-4 F.E. Deng, N. Shivappa, Y. Tang et al. Association between diet-related inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on prediabetics: findings from NHANES III. Eur. J. Nutr. (2016). doi:10.​1007/​s00394-016-1158-4
94.
go back to reference American Cancer Society. Cancer Facts and Figures 2012. (American Cancer Society, Atlanta, GA), (2012) American Cancer Society. Cancer Facts and Figures 2012. (American Cancer Society, Atlanta, GA), (2012)
95.
go back to reference R. Doll, R. Peto, The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66, 1191–1308 (1981)CrossRefPubMed R. Doll, R. Peto, The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66, 1191–1308 (1981)CrossRefPubMed
96.
go back to reference K. Esposito, D. Giugliano, Healthy lifestyle for metabolic health: no more excuse! Endocrine 46(2), 176–178 (2014)CrossRefPubMed K. Esposito, D. Giugliano, Healthy lifestyle for metabolic health: no more excuse! Endocrine 46(2), 176–178 (2014)CrossRefPubMed
97.
go back to reference P.C. Hallal, L.B. Andersen, F.C. Bull, R. Guthold, W. Haskell, U. Ekelund, Lancet Physical Activity Series Working Group, Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380(9838), 247–257 (2012)CrossRefPubMed P.C. Hallal, L.B. Andersen, F.C. Bull, R. Guthold, W. Haskell, U. Ekelund, Lancet Physical Activity Series Working Group, Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380(9838), 247–257 (2012)CrossRefPubMed
98.
go back to reference S.C. Moore, I.M. Lee, E. Weiderpass et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176(6), 816–825 (2016). 1CrossRefPubMedPubMedCentral S.C. Moore, I.M. Lee, E. Weiderpass et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176(6), 816–825 (2016). 1CrossRefPubMedPubMedCentral
Metadata
Title
Insights into the relationships between diabetes, prediabetes, and cancer
Authors
Lorenzo Scappaticcio
Maria Ida Maiorino
Giuseppe Bellastella
Dario Giugliano
Katherine Esposito
Publication date
01-05-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1216-y

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.